Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis

Influence of neoadjuvant chemotherapy on resection of primary colorectal liver metastases: A propensity score analysis

“…In this study, NC was able to increase progression‐free survival even though NC had no influence on OS . However, many of these studies have multiple limitations, such as underpowered statistical analysis due to small patient collectives or lack of sufficient statistical methods . Furthermore, patients with resection of CRLM also received AC after treatment with NC (“perioperative chemotherapy”) .…”

“…In line with these findings is a meta-analysis conducted by Wang et al which shows that the incidence of postoperative complications is significantly higher in patients receiving chemotherapy before surgery compared to patients with surgery alone. 25 In contrast, another retrospective study by Zhu et al showed that NC did not significantly increase complication rates in 466 patients with resectable CRLM. 33 The reason for this discrepancy might be due to the lack of PSM done in the above-mentioned studies.…”

“…4,22 However, many of these studies have multiple limitations, such as underpowered statistical analysis due to small patient collectives or lack of sufficient statistical methods. 25,26 Furthermore, patients with resection of CRLM also received AC after treatment with NC ("perioperative chemotherapy"). 22 The findings of our study are nevertheless completely in line with those studies that do not show any differences in OS of patients with CRLM who receive chemotherapy before surgery compared to patients treated with surgery alone (Fig.…”

Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis

“…Indeed, administration of perioperative chemotherapy is associated with improved DFS. 39,40 In our included studies, the two groups were comparable for perioperative treatment (Table 2); however, this varied within each study, in terms of regimens, duration, and timing of administration (neoadjuvant or adjuvant). Although patient-tailored treatment might have contributed to this variation, it may also be because studies enrolled patients over a long time frame of 20 years (Table 1), during which strategies of perioperative treatment have advanced.…”

Synchronous hepatic metastasis and metachronous Krukenberg tumor from advanced colon cancer. A case report with an unexpected disease-free survival

“…The exact timing of chemotherapy treatment still remains uncertain today; recently 2 interesting meta-analyses of randomized clinical trials [10], [11] have been published in which patients with a colorectal tumor with synchronous resectable liver metastases were treated with perioperative chemotherapy (neoadjuvant and/or adjuvant) with an improvement statistically significant in terms of progression-free survival or disease-free survival. Unfortunately, both studies did not demonstrate an improvement in overall survival.…”